Peter Fellner, the former CEO of Celltech Group plc, built the company into the largest U.K. biotech via M&A. Part of the job of the company's new CEO, Goran Ando, is to show that Celltech can drive growth through its own R&D. While that doesn't exclude more M&A - and may indeed require it to fill in missing skills or simply take advantage of opportunities that are too good to pass up - the test of any biotech company's longevity is its internal innovation.
Last week, Ando discussed with BioCentury the conclusions of his initial review of the company, which was
Read the full 1007 word article